Prudential Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Prudential Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.8K	Sell	20,850 -3,700	-15%	-$9.55K	﹤0.01%	2319
2025 Q4	$33.1K	Buy	24,550 +2,950	+14%	+$4.29K	﹤0.01%	2171
2025 Q3	$32.6K	Buy	21,600 +2,700	+14%	+$4.05K	﹤0.01%	2379
2025 Q2	$21.9K	Sell	18,900 -13,070	-41%	-$17.2K	﹤0.01%	2398
2025 Q1	$50.8K	Buy	31,970 +19,130	+149%	+$41.3K	﹤0.01%	2200
2024 Q4	$38.9K	Buy	+12,840	New	+$42.1K	﹤0.01%	2234
2022 Q1	–	Sell	-2,775	Closed	-$233K	–	2710
2021 Q4	$233K	Buy	+2,775	New	+$215K	﹤0.01%	2491

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Prudential Financial's ZNTL Position: Q1 2026 in Review

Prudential Financial reduced its Zentalis Pharmaceuticals (ZNTL) stake by 15% in Q1 2026, selling an estimated $9.55K and leaving 20,850 shares worth $48.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Prudential Financial first reported a position in ZNTL in Q4 2021 and has held it in 7 quarters since. The position peaked at $233K in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Prudential Financial held 20,850 shares of Zentalis Pharmaceuticals worth $48.8K as of Q1 2026.
Prudential Financial sold 3,700 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $9.55K.
Zentalis Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2319 holding.
Prudential Financial first reported a position in Zentalis Pharmaceuticals in Q4 2021 and has held it in 7 quarters since.
Prudential Financial's Zentalis Pharmaceuticals position peaked at $233K in Q4 2021.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.